Recombinant Antibodies for Immunotherapy

This book provides a comprehensive overview of the field of monoclonal antibodies through twenty-five articles by recognized experts in the field.

Melvyn Little (Edited by)

9780521887328, Cambridge University Press

Hardback, published 27 July 2009

434 pages, 50 b/w illus. 11 colour illus. 32 tables
26 x 18.1 x 2.8 cm, 1.21 kg

Recombinant Antibodies for Immunotherapy provides a comprehensive overview of the field of monoclonal antibodies (mAbs), a market that has grown tremendously in recent years. Twenty-five articles by experienced and innovative authors cover the isolation of specific human mAbs, humanization, immunogenicity, technologies for improving efficacy, 'arming' mAbs, novel alternative Ab constructs, increasing half-lives, alternative concepts employing non-immunoglobulin scaffolds, novel therapeutic approaches, a market analysis of therapeutic mAbs, and future developments in the field. The concepts and technologies are illustrated by examples of recombinant antibodies being used in the clinic or in development. This book will appeal to both newcomers and experienced scientists in the field, biology and biotechnology students, research and development departments in the pharmaceutical industry, medical researchers, clinicians, and biotechnology investors.

Part I. Introduction: 1. Past, present and future of recombinant antibodies G. Winter
Part II. Generation and Screening of Antibody Libraries: 2. Antibody libraries from naïve V gene sources G. Beste and D. Lowe
3. Antibodies from IgM libraries V. Molkenthin and S. Knackmuss
Part III. Transgenic Human Antibody Repertoires: 4. The generation and screening of synthetic antibody libraries I. Klagge
5. Therapeutic antibodies from xenoMouse transgenic mice A. Jakobovits
6. Transgenic chimeric antibodies A. Murphy
Part IV. Humanised Antibodies: 7. Humanization of recombinant antibodies J. Saldanha
8. Immunogenicity assessment of antibody therapeutics P. Stas, J. Pletinckx, Y. Gansemans, and I. Lasters
9. In vitro screening for antibody immunogenicity F. Carr and M. Baker
Part V. Antibody Effector Function: 10. Mechanisms of tumour cell killing by therapeutic antibodies R. Stewart and C. Webster
11. Optimization of Fc domains to enhance antibody therapeutics G. Lazar and A. Chamberlain
12. Glycoengineered therapeutic antibodies P. Brünker, P. Sondermann, and P. Umana
Part VI. Arming Antibodies: 13. Monoclonal antibodies for the delivery of cytotoxic drugs D. King
14. Immunotherapy with radioimmune conjugates C. Kousparou and A. Epenetos
15. Immunotherapeutic antibody fusion proteins N. Courtenay-Luck and D. Jones
Part VII. Antibody Fragments: 16. Alternative antibody formats F. Le Gall and M. Little
17. Single domain antibodies S. Muyldermans
18. Engineering of non-CDR loops in immunoglobulin domains F. Rüker and G. Wozniak-Knopp
Part VIII. Antigen Binding Repertoires of Non-Immunoglobulin Proteins: 19. Alternative antibody scaffolds A. Plueckthun
Part IX. Prolongation of Serum Half Life: 20. Polymer fusions to increase antibody half lives: PEGylation and other modifications S. Heywood and D. Humphreys
21. Extending antibody half-lives with albumin J. Andersen and I. Sandlie
Part X. Current Therapeutic Antibodies and Novel Developments: 22. A stem cell-based platform for the discovery and development of anti-tumor therapeutic antibodies to novel targets J. Mather, C. Fieger, T. Liang, K. King, J. Li, P. Young, C. Beltejar, B. Potts, M. Licea, and D. Loo
23. Antibody directed enzyme prodrug therapy (ADEPT) H. Lowe, S. Sharma, and K. Bagshawe
24. Immune privilege and tolerance - therapeutic antibody approaches D. Forman, P. Ponath, D. Mehta, J. Ponte, J. Snyder, P. Rao, H. Waldmann, and M. Rosenzweig
Part XI. Market Overview and Outlook: 25. Antibody therapeutics: business achievements and business outlook C. Bourrilly.

Subject Areas: Biotechnology [TCB], Immunology [MJCM]